Eloralintide
Metabolic Health · Amylin receptor agonist
Tier B-
Bottom line
Read Off Label grades Eloralintide as B- (5.9/10) based on moderate evidence, high benefit magnitude, and a med-risk safety profile.
Eli Lilly selective amylin agonist.
Typical use: SC once weekly; Phase 2 dose-ranging — Investigational.
What this is
Eli Lilly selective amylin agonist. Phase 2 (n=263, 48 weeks; published Lancet Nov 2025): mean weight loss 9.5-20.1% across doses vs 0.4% placebo, with cardiometabolic improvements and GI adverse events near placebo at lower doses. First long-acting amylin monotherapy beyond pramlintide. Phase 3 enrolling. Industry-sponsored.
Mechanism
Long-acting selective amylin receptor agonist (monotherapy and tirzepatide stack partner); amylin signaling drives satiety and slows gastric emptying independent of GLP-1.
Dose & route
SC once weekly; Phase 2 dose-ranging
Citations
Links go to the source. If a link is dead or you want something re-checked, let me know.
Common questions
- Does Eloralintide work?
- Read Off Label rates the evidence for Eloralintide as Moderate and the benefit magnitude as high, producing an overall grade of B- (5.9/10). Eli Lilly selective amylin agonist.
- Is Eloralintide safe?
- Eloralintide has a med risk profile in published human data. Legal status: Investigational (Phase 3). This is not medical advice — see the disclaimer.
- What is the typical dose for Eloralintide?
- SC once weekly; Phase 2 dose-ranging
- How does Eloralintide work?
- Long-acting selective amylin receptor agonist (monotherapy and tirzepatide stack partner); amylin signaling drives satiety and slows gastric emptying independent of GLP-1.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.